Viewing Study NCT03833167


Ignite Creation Date: 2025-12-25 @ 12:30 AM
Ignite Modification Date: 2026-02-22 @ 7:05 AM
Study NCT ID: NCT03833167
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-24
First Post: 2019-02-04
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Squamous Cell View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Programmed Cell Death-1 (PD-1) View
None Programmed Cell Death 1 View
None PD1 View
None Programmed Cell Death Ligand 1 (PD-L1) View
None Programmed Cell Death Ligand 2 (PD-L2) View
None PDL1 View
None PDL2 View